Shots: The P-III KEYNOTE-426 Study involves assessing of Keytruda (pembrolizumab, 200mg, IV, q3w) + Inlyta (axitinib, 5mg, PO, bid) vs sunitinib (50 mg, PO, qd@4w) monothx in 861 patients with […]readmore
Tags : KEYNOTE-426 Study